-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 11, the official website of NMPA showed that Xintai Pharmaceutical's Oxiracetam injection was approved for marketing.
Oxiracetam injection is an analogue of piracetam, which can improve the memory and learning function of patients with senile dementia and memory disorders.
According to data from Minaiwang, in recent years, the terminal sales of Oxiracetam injection in Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have continued to decline, from 8 billion in 2016.
Sales of Oxiracetam Terminals in Public Medical Institutions in China
Source: Mi Nei.
At present, Oxiracetam products marketed in China involve three dosage forms: injections, capsules and tablets.
Oxiracetam injection listing application enterprise under review
Source: Meinenet MED2.
The manufacturer of Oxiracetam tablets only has North China Pharmaceutical, and there are 2 manufacturers of Oxiracetam capsules and Oxiracetam for injection.
Source: Mi Neiwang database, NMPA